Bos Sci launches Taxus Element in EU
Boston Scientific has launched its Taxus Element paclitaxel-eluting coronary stent system in the European Union and other CE Mark countries, after which the first implants took place.
According to the company, the Taxus Element Stent System is its third-generation drug-eluting stent technology and incorporates a platinum chromium alloy and a catheter delivery system. It received CE Mark approval last month, which included an indication for the treatment of diabetic patients.
The first European implants were performed by Corrado Tamburino, MD, PhD, chair of the cardiology department at Ferrarotto Hospital in Catania, Italy, and Adrian Banning, MD, directorate chair of cardiac services at John Radcliffe Hospital in Oxford, England.
The Natick, Mass.-based Boston Scientific received CE Mark approval for the Promus Element everolimus-eluting stent system in October 2009. Both Element stent systems incorporate the same platinum chromium alloy stent design and catheter delivery system.
According to the company, the Taxus Element Stent System is its third-generation drug-eluting stent technology and incorporates a platinum chromium alloy and a catheter delivery system. It received CE Mark approval last month, which included an indication for the treatment of diabetic patients.
The first European implants were performed by Corrado Tamburino, MD, PhD, chair of the cardiology department at Ferrarotto Hospital in Catania, Italy, and Adrian Banning, MD, directorate chair of cardiac services at John Radcliffe Hospital in Oxford, England.
The Natick, Mass.-based Boston Scientific received CE Mark approval for the Promus Element everolimus-eluting stent system in October 2009. Both Element stent systems incorporate the same platinum chromium alloy stent design and catheter delivery system.